A 12-week Phase 2/3 study in 351 patients with mild to moderate Alzheimer’s disease reported statistically significant, dose-dependent improvements on ADAS-Cog11 in pTau217-positive patients with mild disease (MMSE 21–24). At the 30 mg dose, effects were consistent across age, BMI, sex, ethnicity, ApoE4 status, and concomitant medications. Safety was comparable to placebo across all arms, including in ApoE4 carriers. Biomarker analyses showed reductions in tau and TDP-43, decreases in inflammatory markers (IL-5, IL-6, S100A12, IFN-γ, IGF1R), and lower neurofilament light chain, with similar biomarker trends observed in moderate disease.
The core development is twofold: Annovis Bio has published the Phase 2/3 results of oral buntanetap in Nature npj Dementia and is nearing full enrollment (approximately 80%) in a pivotal Phase 3 trial in early AD that restricts enrollment to pTau217-positive patients (MMSE 20–28). The registrational study is designed to read out symptomatic efficacy at six months and potential disease modification at 18 months, aiming to replicate and extend the earlier cognitive and biomarker signals while maintaining background symptomatic therapies.
Strategically, this is a bid to carve out an oral, biomarker-enriched, safety-forward position against an Alzheimer’s landscape dominated by anti-amyloid antibodies that carry infusion logistics and ARIA risk. Enrichment with plasma pTau217 tightens the disease biology and aligns with the field’s move toward blood-based diagnostics to improve trial signal-to-noise and enrollment velocity. The package leans on two levers: a cognitive signal in a biologically confirmed early AD subset and a broad biomarker footprint that gestures toward disease modification via translational inhibition of multiple neurotoxic proteins. The tension is familiar: short-duration cognitive gains must translate into durable functional benefit, and diverse biomarker shifts must map to clinical outcomes regulators prioritize. The choice of ADAS-Cog11 as a key readout will invite scrutiny alongside CDR-SB and other functional measures in Phase 3, where multiplicity, durability, and trajectory of decline will be decisive.
For sites and CROs, the operational story is the growing centrality of plasma pTau217. Trials that can stand up reliable, rapid, and reproducible pTau217 screening gain an enrollment and data-quality edge; those without established plasma workflows face throughput risks. Community sites could benefit from an oral regimen that permits continuation of background symptomatic meds, potentially broadening geographic reach versus infusion-dependent trials, while central labs and assay vendors see increased demand for standardized pTau217 testing and longitudinal NfL monitoring. Sponsors tracking AD development should note the feasibility signal implied by 80% enrollment under a biomarker-gated design. Regulators are likely to focus on the linkage between the biomarker panel and clinically meaningful endpoints over 18 months, particularly given the modest absolute effect sizes that have characterized small-molecule attempts in AD.
The next inflection points are full Phase 3 enrollment, six-month cognitive data, and 18-month outcomes that test whether the biomarker shifts correspond to slowed decline. Watch for assay harmonization and cutoff consistency for pTau217 across regions, dropout rates in ApoE4 carriers, and whether benefits persist when stratifying by concomitant medication classes. The durability of effect, the hierarchy and control of multiple endpoints, and clarity on functional measures will determine whether an oral, multi-target approach can secure a regulatory path amid antibody incumbents. If the Phase 3 confirms both symptomatic and disease-modifying signals, buntanetap could reshape operational norms toward blood-based enrichment and oral regimens; if not, the field’s center of gravity remains with antibody programs and combination strategies.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
